United States set
Menu Shopping cart $0 Search
Distributed product


  • Regulatory status:RUO
  • Type:Competitive ELISA, Immobilized antigen
  • Other names:Symmetric Dimethylarginine
  • Species:Dog, Feline
This product is not available in United States!
Cat. No. Size Price

EA203/96 96 wells (1 kit)
PubMed Product Details
Technical Data


Competitive ELISA, Immobilized antigen


The competitive SDMA-ELISA uses the microtiter plate format. SDMA is bound to the solid phase of the microtiter plate. SDMA in the samples is acylated and competes with solid phase bound SDMA for a fixed number of rabbit anti-SDMA antiserum binding sites. When the system is in equilibrium, free antigen and free antigen-antiserum complexes are removed by washing. The antibody bound to the solid phase SDMA is detected by anti-rabbit / peroxidase. The substrate TMB / peroxidase reaction is monitored at 450 nm. The amount of antibody bound to the solid phase SDMA is inversely proportional to the SDMA concentration of the sample.


Serum, Plasma-EDTA

Sample Requirements

20 μl/well


On blue ice packs. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

0–3.0 µmol/l

Limit of Detection

0.03 μmol/l

Intra-assay (Within-Run)

Cat: 5,7
Dog: 5,9%, n = 40

Inter-assay (Run-to-Run)

Cat: 7.3%
Dog: 7%, n = 32

Spiking Recovery

Cat: 97% (90-104%)
Dog: 104%

Dilution Linearity

Cat: 96%
Dog: 92%



  • for veterinary diagnostic
  • Material of animal origin used in the preparation of the kit has been obtained from animals certified as healthy but these materiále should be handled as potentially infectious
  • standard 1-6 : 0–3.0 µmol/l (0-606 ng/ml)
  • limit of detection 0.03 μmol/l

Research topic

Renal disease, Animal studies


Symmetric dimethylarginine (SDMA) is a methylated arginine amino acid. SDMA is derived from intranuclear methylation of L-arginine residues and is released into the cytoplasm after proteolysis. SDMA is excreted by the kidneys. Several studies have found that 1 in 3 cats and 1 in 10 dogs are likely to develop a kidney disease during their lifetime. SDMA is an early biomarker of kidney function. It correlates well with glomerular filtration rate (GFR). On average, SDMA increases in chronic kidney disease (CKD) with 30 to 40% loss of kidney function. Creatinine, however, does not increase until 75% of kidney function is lost. SDMA will enable veterinarians to diagnose chronic kidney disease (CKD) much earlier than Creatinine or Cystatin C tests. SDMA is specific for kidney function. It is not impacted by other diseases such as liver disease, cardiovascular disease, inflammatory disease and endocrine diseases. Another exciting feature of SDMA is that it is not impacted by muscle mass either, which simplifies diagnosing and monitoring CKD in thin geriatric animals, especially cats and animals with other diseases that cause muscle wasting.

Product References (3)


  • Bode-Boger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, Fobker M, Reinecke H. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol. 2006 Apr;17 (4):1128-34
  • Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. Nephrol Dial Transplant. 2006 Sep;21 (9):2446-51
  • Wanby P, Teerlink T, Brudin L, Brattstrom L, Nilsson I, Palmqvist P, Carlsson M. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis. 2006 Apr;185 (2):271-7
Related Products Docs